紫杉醇联合顺铂治疗Ⅲb和Ⅳ期非小细胞肺癌的临床观察

目的：观察紫杉醇联合顺铂治疗晚期非小细胞肺癌患者的临床疗效及毒副反应。方法：经病理或细胞学证实的Ⅲb期和Ⅳ期非小细胞肺癌患者21例，紫杉醇，170mg／m。。加入0．9％生理盐水中静滴4～6h，第1天；顺铂30mg／0。第1、2、3天静滴。结果：37例患者中CR2例，PR17例，SD12例，PD6例，总有效率（CR＋PR）51．3％，临床获益率（CR＋PR＋SD）83．7％，主要的毒副反应为骨髓抑制、消化道反应及肌肉酸痛，绝大多数患者能够耐受。结论：紫杉醇联合顺铂治疗晚期非小细胞肺癌患者疗效确切，副反应能够耐受，值得推广。

Paclitaxel and Cislatin in Treatment of Advanced NSCLC

Objective：To observe the effect and side effect in patients of advanced non - small cell lung cancer receiving chemotherapy with eisplatin and paelitaxel. Methods：The 37 patients of advanced non - small cell cancer were verived by cytology or pathology. Paclitaxel 170mg/m2 D1 iv drip, eisplatin 30mg/m2 D1,2,3 iv drip. Results：The eases of CR, PR and SD in 37 patients were 2, 17 and 12. The general response rate was 51.3%. The main side effect was myelosuppression, and muscular soreness. Almost all the patients could tolerate the side effect. Conclusion： The effect of chemotherapy with cisplatin and paclitaxel to the patient of advanced non - small cell lung cancer was certain, most patients could tolerate the therapy, this regime was worthwhile to be extended.